Study of a new pill for advanced solid tumors with a missing PTEN protein
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests an experimental pill (CVL237) for people with advanced solid tumors that lack a protein called PTEN. The study aims to see if the pill can help control the cancer and shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have an advanced solid tumor that has not responded to standard treatment, or no standard treatment exists, or you choose not to receive standard treatment.
- Your tumor test shows a lack of the PTEN protein.
- You have at least one measurable tumor that can be seen on a scan (e.g., CT or MRI).
- You are generally well enough to perform daily activities (ECOG score 0-2).
- Your blood counts, liver and kidney function are within acceptable limits for the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called TT-702, either alone or with an immunotherapy drug, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or slow the growth of tumors.
This trial tests a new pill called ASN-3186 for people with advanced solid tumors that haven't responded to standard treatments. The drug may work especially well if your cancer has certain DNA repair problems, like a BRCA mutation.
This trial tests a new tablet called GEN-725 for people with advanced solid tumors that have stopped responding to standard treatments or cannot tolerate them. It aims to see if the drug is safe and how it affects the body, and may be an option if you've had prior treatment with PD-1/PD-L1 inhibitors that stopped working at least 6 months ago.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.